Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• Dimensional Fund Advisors increased its BeOne Medicines stake by 15.9% in the first quarter, bringing its holdings to 56,879 shares worth approximately $16.9 million. Institutional investors collectively own 48.55% of the company.
• BeOne reported a strong second quarter, with adjusted earnings of $2.05 per share and revenue of $1.71 billion, exceeding analyst estimates. Management also raised its 2026 revenue outlook to approximately $6.6 billion-$6.8 billion.
• Analysts have generally turned more bullish, with several firms raising price targets and the stock carrying a “Moderate Buy” consensus rating. However, BeOne’s elevated valuation and recent insider selling—including a large CEO sale under a pre-arranged plan—remain potential risks.

Dimensional Fund Advisors LP increased its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 15.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,879 shares of the company's stock after buying an additional 7,815 shares during the quarter. Dimensional Fund Advisors LP owned about 0.05% of BeOne Medicines worth $16,859,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ONC. EFG International AG bought a new position in BeOne Medicines in the fourth quarter worth approximately $25,000. Leonteq Securities AG purchased a new stake in BeOne Medicines in the fourth quarter worth about $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the 2nd quarter worth about $35,000. CWM LLC grew its holdings in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new position in BeOne Medicines during the 4th quarter valued at about $61,000. Institutional investors own 48.55% of the company's stock.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ONC shares. Nomura raised shares of BeOne Medicines to a "strong-buy" rating in a research report on Monday, July 27th. TD Cowen increased their price objective on BeOne Medicines from $424.00 to $454.00 and gave the company a "buy" rating in a report on Thursday. Morgan Stanley restated an "overweight" rating on shares of BeOne Medicines in a research note on Thursday. JPMorgan Chase & Co. upped their target price on BeOne Medicines from $415.00 to $425.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BeOne Medicines in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, BeOne Medicines has a consensus rating of "Moderate Buy" and an average target price of $400.00.

Insider Activity

In other BeOne Medicines news, CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $312.71, for a total transaction of $361,805.47. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of the firm's stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the sale, the chief executive officer owned 9,180 shares of the company's stock, valued at $2,916,210.60. This represents a 86.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 345,561 shares of company stock valued at $105,625,947 in the last ninety days. 6.19% of the stock is currently owned by company insiders.

BeOne Medicines Price Performance

NASDAQ:ONC opened at $348.27 on Friday. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.27 and a current ratio of 3.40. The stock has a market cap of $38.21 billion, a PE ratio of 61.32 and a beta of 0.49. The stock has a 50 day moving average price of $296.52 and a 200 day moving average price of $308.89.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post 6.26 EPS for the current fiscal year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source